...that started out in the labs of Organon, which was looking for autoimmune disease treatments. Organon...
...financial resources into developing Keytruda at a speed and with an intensity that Schering and Organon...

...Matthew Walsh as CFO and Rachel Stahler as chief information officer of its planned spinout Organon...
...to complete the spin out of its women’s health business, legacy brands and biosimilars into Organon...

...and CSO of pain company Kadmus Pharmaceuticals Inc. , which sold its key assets to Organon BioSciences N.V....

...its 2009 acquisition of Schering-Plough Corp. Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....

...sequence and expression database and LifeSeq GeneAlbum reagent set in exchange for annual access fees. Organon...
...collaboration. INCY is eligible to receive royalties. Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. NV Organon...

...for milestones and royalties. Organon has all rights to develop and commercialize the humanized antibody. Organon...

...reactions" (see BioCentury, Aug. 4, 2008). Schering-Plough gained the compound through its 2007 acquisition of Organon BioSciences N.V....

...Merck's Organon N.V. subsidiary proposed to restructure and reduce headcount of R&D at Dutch sites Oss...
...reduce headcount of R&D at Dutch sites Oss and Schaijk by 551 (53%) to 479. Organon...